Aditxt ADTX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Aditxt (ADTX)
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
Key Insights
Critical company metrics and information
Latest Closing Price
$0.0515Market Cap
$4.06 MillionPrice-Earnings Ratio
-0.00Total Outstanding Shares
78.89 Million SharesTotal Employees
47Dividend
No dividendIPO Date
June 30, 2020SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQType
Common StockHeadquarters
737 n. fifth street, suite 200, Richmond, VA, 23219Homepage
https://www.aditxt.com
Historical Stock Splits
If you bought 80,000 shares of ADTX before September 14, 2022, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| October 2, 2024 | 1-for-40 (Reverse Split) |
| August 18, 2023 | 1-for-40 (Reverse Split) |
| September 14, 2022 | 1-for-50 (Reverse Split) |
Cash Flow Statement
April 1, 2023 to March 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-20.59 Million |
| Net Cash Flow From Operating Activities | $-20.59 Million |
| Net Cash Flow From Financing Activities | $20.38 Million |
| Net Cash Flow, Continuing | $-205,407 |
| Net Cash Flow From Investing Activities | $-927 |
| Net Cash Flow From Investing Activities, Continuing | $-927 |
Income Statement
April 1, 2023 to March 31, 2024
| Metric | Value |
|---|---|
| Basic Earnings Per Share | $-30.04 |
| Revenues | $506,441 |
| Gross Profit | $-137,885 |
| Net Income/Loss Available To Common Stockholders, Basic | $-41.45 Million |
| Benefits Costs and Expenses | $41.78 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $-42.97 Million |
Comprehensive Income
April 1, 2023 to March 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-84.10 Million |
| Comprehensive Income/Loss | $-84.10 Million |
Balance Sheet
April 1, 2023 to March 31, 2024
| Metric | Value |
|---|---|
| Assets | $27.98 Million |
| Equity Attributable To Parent | $9.93 Million |
| Equity | $9.78 Million |
| Current Assets | $1.60 Million |
| Equity Attributable To Noncontrolling Interest | $-148,575 |
| Intangible Assets | $8,611 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ADTX from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.